Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CAR T-cell Therapy”

1,363 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,363 results

Early research (Phase 1)Looking for participantsNCT07007117
What this trial is testing

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Who this might be right for
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-Risk Neuroblastoma
Stephan Grupp MD PhD 38
Testing effectiveness (Phase 2)UnknownNCT05315778
What this trial is testing

Anti-BCMA CAR T-Cell Therapy for R/R ITP

Who this might be right for
ITP
The First Affiliated Hospital of Soochow University 5
Early research (Phase 1)UnknownNCT05474885
What this trial is testing

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Who this might be right for
Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
iCell Gene Therapeutics 15
Not applicableLooking for participantsNCT07609485
What this trial is testing

Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy

Who this might be right for
CancerHematologic Malignancy
University Hospital, Lille 700
Testing effectiveness (Phase 2)Looking for participantsNCT07341191
What this trial is testing

Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy

Who this might be right for
Mantle Cell Lymphoma
Canadian Cancer Trials Group 40
Testing effectiveness (Phase 2)Looking for participantsNCT05652920
What this trial is testing

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Who this might be right for
Hepatocellular Carcinoma
OriCell Therapeutics Co., Ltd. 105
Early research (Phase 1)UnknownNCT04861480
What this trial is testing

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Chongqing Precision Biotech Co., Ltd 18
Not applicableUnknownNCT06041815
What this trial is testing

Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies

Who this might be right for
Hematological MalignanciesChimeric Antigen Receptor T-cell Therapy
The First Affiliated Hospital of Soochow University 100
Very early researchLooking for participantsNCT07144020
What this trial is testing

Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Zhejiang University 50
Very early researchUnknownNCT04966143
What this trial is testing

Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Shanghai Longyao Biotechnology Inc., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Not applicableUnknownNCT05414162
What this trial is testing

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Who this might be right for
DLBCLMultiple MyelomaCytokine Release Syndrome+6 more
University Hospital, Bonn 60
Testing effectiveness (Phase 2)Looking for participantsNCT05594797
What this trial is testing

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 100
Early research (Phase 1)WithdrawnNCT03904069
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Amgen
Testing effectiveness (Phase 2)Looking for participantsNCT07109323
What this trial is testing

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Who this might be right for
Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High RiskPrimary Refractory+4 more
Institute of Hematology & Blood Diseases Hospital, China 50
Testing effectiveness (Phase 2)Study completedNCT04601831
What this trial is testing

'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL

Who this might be right for
Non-Hodgkin Lymphoma
University of Texas Southwestern Medical Center 14
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Very early researchUnknownNCT04156269
What this trial is testing

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iCell Gene Therapeutics 12
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)UnknownNCT05596266
What this trial is testing

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

Who this might be right for
T-cell Acute Lymphoblastic Leukemia
Xuanwu Hospital, Beijing 20
Load More Results